Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives t ...

Ironwood Pharmaceuticals (IRWD) reported an adjusted loss of 14 cents per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had reported an adjusted loss of 2 cents per share in the year-ago quarter.Total revenues in the first quarter were $41.1 million, which also missed the Zacks Consensus Estimate of $59 million. Revenues decreased around 45.1% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Sh ...